{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:48:21Z","timestamp":1786996101035,"version":"build-2736575974"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.pupt.2021.102030","type":"journal-article","created":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T09:38:02Z","timestamp":1617529082000},"page":"102030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant"],"prefix":"10.1016","volume":"68","author":[{"given":"Chris","family":"Brightling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swarupa","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart N.","family":"Lambrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4523-9931","authenticated-orcid":false,"given":"David","family":"Sandham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4799-903X","authenticated-orcid":false,"given":"Pablo","family":"Altman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2021.102030_bib1","doi-asserted-by":"crossref","first-page":"105859","DOI":"10.1016\/j.rmed.2019.105859","article-title":"One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting \u03b2(2)-agonist in UK primary care settings","volume":"162","author":"Buhl","year":"2020","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.pupt.2021.102030_bib2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12931-018-0893-x","article-title":"The prostaglandin D2 receptor 2 pathway in asthma: a key player in airway inflammation","volume":"19","author":"Domingo","year":"2018","journal-title":"Respir. Res."},{"key":"10.1016\/j.pupt.2021.102030_bib3","first-page":"165","article-title":"CRTH2 antagonists in asthma: current perspectives","volume":"9","author":"Singh","year":"2017","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.pupt.2021.102030_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13543784.2019.1555237","article-title":"Prostaglandin D2 receptor antagonists in allergic disorders: safety, efficacy, and future perspectives","volume":"28","author":"Marone","year":"2019","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.pupt.2021.102030_bib6","author":"GB001"},{"issue":"2","key":"10.1016\/j.pupt.2021.102030_bib7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.pharmthera.2004.06.003","article-title":"Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation","volume":"103","author":"Hata","year":"2004","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.pupt.2021.102030_bib8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0092-8674(95)90407-7","article-title":"Heterotrimeric G proteins: organizers of transmembrane signals","volume":"80","author":"Neer","year":"1995","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.pupt.2021.102030_bib9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/pr.110.003517","article-title":"International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress","volume":"63","author":"Woodward","year":"2011","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.pupt.2021.102030_bib10","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000313836","article-title":"CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases","volume":"85","author":"Schuligoi","year":"2010","journal-title":"Pharmacology"},{"issue":"4","key":"10.1016\/j.pupt.2021.102030_bib11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.molmed.2006.02.005","article-title":"Emerging roles of DP and CRTH2 in allergic inflammation","volume":"12","author":"Kostenis","year":"2006","journal-title":"Trends Mol. Med."},{"issue":"Suppl 1","key":"10.1016\/j.pupt.2021.102030_bib12","first-page":"S191","article-title":"The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses","volume":"153","author":"Pettipher","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.pupt.2021.102030_bib13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1476-5381.1989.tb11816.x","article-title":"The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist","volume":"96","author":"Giles","year":"1989","journal-title":"Br. J. Pharmacol."},{"issue":"Suppl","key":"10.1016\/j.pupt.2021.102030_bib14","doi-asserted-by":"crossref","first-page":"S423","DOI":"10.1194\/jlr.R800094-JLR200","article-title":"Prostanoids in health and disease","volume":"50","author":"Smyth","year":"2009","journal-title":"J. Lipid Res."},{"issue":"10","key":"10.1016\/j.pupt.2021.102030_bib15","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.4049\/jimmunol.170.10.4943","article-title":"Prostaglandin D2 affects the maturation of human monocyte-derived dendritic cells: consequence on the polarization of naive Th cells","volume":"170","author":"Gosset","year":"2003","journal-title":"J. Immunol."},{"issue":"5460","key":"10.1016\/j.pupt.2021.102030_bib16","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1126\/science.287.5460.2013","article-title":"Prostaglandin D2 as a mediator of allergic asthma","volume":"287","author":"Matsuoka","year":"2000","journal-title":"Science (New York, N.Y.)"},{"issue":"2","key":"10.1016\/j.pupt.2021.102030_bib17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1084\/jem.20061196","article-title":"Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells","volume":"204","author":"Hammad","year":"2007","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.pupt.2021.102030_bib18","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jaci.2009.07.006","article-title":"Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis","volume":"124","author":"Philip","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"issue":"440","key":"10.1016\/j.pupt.2021.102030_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao0052","article-title":"PGD2\/DP2 receptor activation promotes severe viral bronchiolitis by suppressing IFN-lambda production","volume":"10","author":"Werder","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.pupt.2021.102030_bib20","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41385-018-0049-9","article-title":"Synergistic activation of pro-inflammatory type-2 CD8(+) T lymphocytes by lipid mediators in severe eosinophilic asthma","volume":"11","author":"Hilvering","year":"2018","journal-title":"Mucosal Immunol."},{"issue":"11","key":"10.1016\/j.pupt.2021.102030_bib21","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ni.2104","article-title":"Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161","volume":"12","author":"Mjosberg","year":"2011","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.pupt.2021.102030_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108595","article-title":"Expression of DP2 (CRTh2), a prostaglandin D(2) receptor, in human mast cells","volume":"9","author":"Moon","year":"2014","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.pupt.2021.102030_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0014-5793(99)01251-X","article-title":"CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s)","volume":"459","author":"Nagata","year":"1999","journal-title":"FEBS Lett."},{"issue":"3","key":"10.1016\/j.pupt.2021.102030_bib24","first-page":"1278","article-title":"Selective expression of a novel surface molecule by human Th2 cells in vivo","volume":"162","author":"Nagata","year":"1999","journal-title":"J. Immunol. (Baltim., Md.)"},{"issue":"479","key":"10.1016\/j.pupt.2021.102030_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao6451","article-title":"DP2 antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment","volume":"11","author":"Saunders","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.pupt.2021.102030_bib26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaci.2014.08.027","article-title":"D prostanoid receptor 2 (chemoattractant receptor-homologous molecule expressed on TH2 cells) protein expression in asthmatic patients and its effects on bronchial epithelial cells","volume":"135","author":"Stinson","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.pupt.2021.102030_bib27","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaci.2016.12.958","article-title":"Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines","volume":"140","author":"Salimi","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.pupt.2021.102030_bib28","first-page":"694","article-title":"Leukotriene E4 activates human Th2 cells for exaggerated proinflammatory cytokine production in response to prostaglandin D2","volume":"188","author":"Xue","year":"2012","journal-title":"J. Immunol. (Baltim., Md.)"},{"issue":"4","key":"10.1016\/j.pupt.2021.102030_bib29","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jaci.2013.10.056","article-title":"Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells","volume":"133","author":"Xue","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2021.102030_bib30","series-title":"Fevipiprant Antagonises Prostaglandin D2-Induced Activation of Type-2 CD8+ T Cells (Tc2)","first-page":"OA4953","author":"Chen","year":"2019"},{"issue":"6","key":"10.1016\/j.pupt.2021.102030_bib31","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.jaci.2018.10.069","article-title":"Cytokine-induced endogenous production of prostaglandin D2 is essential for human group 2 innate lymphoid cell activation","volume":"143","author":"Maric","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.pupt.2021.102030_bib32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1124\/mol.115.101832","article-title":"Fevipiprant (QAW039), a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy","volume":"89","author":"Sykes","year":"2016","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.pupt.2021.102030_bib33","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jaci.2018.07.011","article-title":"In vivo imaging reveals increased eosinophil uptake in the lungs of obese asthmatic patients","volume":"142","author":"Farahi","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2021.102030_bib34","series-title":"Effect of Timapiprant, a DP2 Antagonist, on Airway Inflammation in Severe Eosinophilic Asthma","author":"Shrimanker","year":"2019"},{"issue":"7","key":"10.1016\/j.pupt.2021.102030_bib36","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1021\/jm2013997","article-title":"Update on the development of antagonists of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). From lead optimization to clinical proof-of-concept in asthma and allergic rhinitis","volume":"55","author":"Pettipher","year":"2012","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.pupt.2021.102030_bib37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.molcel.2018.08.009","article-title":"Structures of the human PGD2 receptor CRTH2 reveal novel mechanisms for ligand recognition","volume":"72","author":"Wang","year":"2018","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.pupt.2021.102030_bib38","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1021\/acsmedchemlett.7b00157","article-title":"Discovery of fevipiprant (NVP-QAW039), a potent and selective DP2 receptor antagonist for treatment of asthma","volume":"8","author":"Sandham","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.pupt.2021.102030_bib39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.febslet.2005.11.052","article-title":"9alpha,11beta-PGF2 and its stereoisomer PGF2alpha are novel agonists of the chemoattractant receptor, CRTH2","volume":"580","author":"Sandig","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.pupt.2021.102030_bib40","series-title":"D.A. Fevipiprant Inhibits Eosinophil Activation Induced by Multiple Metabolites of Prostaglandin D2","author":"Carstensen","year":"2019"},{"key":"10.1016\/j.pupt.2021.102030_bib41","unstructured":"Novartis, Data on File."},{"issue":"2","key":"10.1016\/j.pupt.2021.102030_bib42","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/cea.13304","article-title":"Fevipiprant, a DP2 receptor antagonist, inhibits eosinophil migration towards mast cells, Clinical and experimental allergy","volume":"49","author":"Shamri","year":"2019","journal-title":"J. Br. Soc. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2021.102030_bib43","first-page":"A1418","article-title":"Fevipiprant, a potent selective prostaglandin D2 receptor 2 (DP2) antagonist, dose-dependently inhibits pulmonary inflammation in a mouse model of asthma","volume":"197","author":"Sandham","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.pupt.2021.102030_bib44","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/cea.12741","article-title":"Elevated levels of circulating CD4(+) CRTh2(+) T cells characterize severe asthma","volume":"46","author":"Palikhe","year":"2016","journal-title":"Clin. Exp. Allergy : J. Br. Soc. Allergy Clin. Immunol."},{"issue":"suppl 63","key":"10.1016\/j.pupt.2021.102030_bib45","first-page":"OA3808","article-title":"Fevipiprant is superior to montelukast in suppressing type 2 cytokine production from mast cell stimulated human Th2 cells","volume":"54","author":"Kazani","year":"2019","journal-title":"ERJ (Abstr.)"},{"issue":"1","key":"10.1016\/j.pupt.2021.102030_bib46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1183\/09031936.04.00008104","article-title":"Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma","volume":"25","author":"Jayaram","year":"2005","journal-title":"Eur. Respir. J."},{"issue":"9","key":"10.1016\/j.pupt.2021.102030_bib47","first-page":"699","article-title":"Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial, the Lancet","volume":"4","author":"Gonem","year":"2016","journal-title":"Respir. Med."},{"issue":"3","key":"10.1016\/j.pupt.2021.102030_bib48","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jaci.2014.06.024","article-title":"Enhanced innate type 2 immune response in peripheral blood from patients with asthma","volume":"134","author":"Bartemes","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.pupt.2021.102030_bib49","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jaci.2019.02.015","article-title":"Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function","volume":"143","author":"Hardman","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2021.102030_bib50","first-page":"A3826","article-title":"Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, potently inhibits chemotaxis and cytokine production by Tc2 cells (type-2 CD8+lymphocytes)","volume":"199","author":"Xue","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.pupt.2021.102030_bib51","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/cpdd.244","article-title":"Pharmacokinetics, safety, and tolerability of fevipiprant (QAW039), a novel CRTh2 receptor antagonist: results from 2 randomized, phase 1, placebo-controlled studies in healthy volunteers","volume":"5","author":"Erpenbeck","year":"2016","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"7","key":"10.1016\/j.pupt.2021.102030_bib52","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1124\/dmd.117.075358","article-title":"Absorption, distribution, metabolism, and excretion of the oral prostaglandin D2 receptor 2 antagonist fevipiprant (QAW039) in healthy volunteers and in vitro","volume":"45","author":"Pearson","year":"2017","journal-title":"Drug Metabol. Dispos.: Biol. Fate Chem."},{"key":"10.1016\/j.pupt.2021.102030_bib53","first-page":"PA4693","article-title":"Fevipiprant (QAW039) demonstrates safety, tolerability and consistent PK at high oral doses","volume":"50","author":"Erpenbeck","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2021.102030_bib54","series-title":"A Study of the Effect of Cyclosporine on Fevipiprant Pharmacokinetics and its Absolute Bioavailability Using an Intravenous Microdose Approach, Drug Metabolism and Disposition: the Biological Fate of Chemicals","author":"Weiss","year":"2020"},{"key":"10.1016\/j.pupt.2021.102030_bib55","series-title":"Fevipiprant Has a Low Risk of Influencing Co-medication Pharmacokinetics: Impact on Simvastatin and Rosuvastatin in Different SLCO1B1 Genotypes, Pulmonary Pharmacology & Therapeutics","first-page":"101809","author":"Poller","year":"2019"},{"issue":"2","key":"10.1016\/j.pupt.2021.102030_bib56","first-page":"55","article-title":"LUSTER-1 and -2: two randomized controlled trials of the prostaglandin D2 receptor 2 antagonist, fevipiprant, in asthma","volume":"9","author":"Brightling","year":"2019","journal-title":"Clin. Invest."},{"issue":"11","key":"10.1016\/j.pupt.2021.102030_bib57","first-page":"879","article-title":"Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study, the Lancet","volume":"2","author":"Castro","year":"2014","journal-title":"Respir. Med."},{"issue":"10","key":"10.1016\/j.pupt.2021.102030_bib58","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"9842","key":"10.1016\/j.pupt.2021.102030_bib59","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.pupt.2021.102030_bib60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2213-2600(20)30412-4","article-title":"Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials","volume":"9","author":"Brightling","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"6","key":"10.1016\/j.pupt.2021.102030_bib61","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.jaci.2013.01.035","article-title":"Prostaglandin D(2) pathway upregulation: relation to asthma severity, control, and TH2 inflammation","volume":"131","author":"Fajt","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.pupt.2021.102030_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/13993003.00670-2017","article-title":"Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids","volume":"50","author":"Bateman","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2021.102030_bib64","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pupt.2016.06.005","article-title":"The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma","volume":"39","author":"Erpenbeck","year":"2016","journal-title":"Pulm. Pharmacol. Therapeut."},{"issue":"5","key":"10.1016\/j.pupt.2021.102030_bib65","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.pupt.2021.102030_bib66","first-page":"197","article-title":"Relationships between eosinophilic inflammation, tissue remodeling, and fibrosis in eosinophilic esophagitis","volume":"29","author":"Aceves","year":"2009","journal-title":"Immunol. Allergy Clin."},{"issue":"3","key":"10.1016\/j.pupt.2021.102030_bib67","first-page":"1538","article-title":"Evidence for local eosinophil differentiation within allergic nasal mucosa: inhibition with soluble IL-5 receptor","volume":"164","author":"Cameron","year":"2000","journal-title":"J. Immunol. (Baltim., Md.)"},{"issue":"2","key":"10.1016\/j.pupt.2021.102030_bib68","first-page":"358","article-title":"Interleukin-5 is the predominant eosinophilopoietin produced by cloned T lymphocytes in hypereosinophilic syndrome","volume":"21","author":"Schrezenmeier","year":"1993","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.pupt.2021.102030_bib69","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2500\/108854199778681486","article-title":"Eosinophil active cytokines and surface analysis of eosinophils in Churg-Strauss syndrome","volume":"20","author":"Tsukadaira","year":"1999","journal-title":"Allergy Asthma Proc."},{"issue":"9","key":"10.1016\/j.pupt.2021.102030_bib70","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/all.12451","article-title":"Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459","volume":"69","author":"Pettipher","year":"2014","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.pupt.2021.102030_bib71","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"12","key":"10.1016\/j.pupt.2021.102030_bib72","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.4049\/jimmunol.1101806","article-title":"Eosinophils as a novel cell source of prostaglandin D2: autocrine role in allergic inflammation","volume":"187","author":"Luna-Gomes","year":"2011","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.pupt.2021.102030_bib73","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.jaci.2018.10.069","article-title":"Cytokine-induced endogenous production of PGD2 is essential for human ILC2 activation","volume":"143","author":"Maric","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2021.102030_bib74","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","article-title":"Asthma","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.pupt.2021.102030_bib75","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fimmu.2013.00104","article-title":"Interleukin-33: a mediator of inflammation targeting hematopoietic stem and progenitor cells and their progenies","volume":"4","author":"Le","year":"2013","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.pupt.2021.102030_bib76","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.4049\/jimmunol.129.4.1627","article-title":"2nd, Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE","volume":"129","author":"Lewis","year":"1982","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.pupt.2021.102030_bib77","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.4049\/jimmunol.164.5.2277","article-title":"Cutting edge: differential production of prostaglandin D2 by human helper T cell subsets","volume":"164","author":"Tanaka","year":"2000","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.pupt.2021.102030_bib78","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.4049\/jimmunol.143.9.2982","article-title":"The major source of endogenous prostaglandin D2 production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues","volume":"143","author":"Urade","year":"1989","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.pupt.2021.102030_bib79","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.4049\/jimmunol.168.7.3563","article-title":"15-Deoxy-delta 12,14-prostaglandins D2 and J2 are potent activators of human eosinophils","volume":"168","author":"Monneret","year":"2002","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.pupt.2021.102030_bib80","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1067\/mai.2001.119919","article-title":"Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP","volume":"108","author":"Gervais","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.pupt.2021.102030_bib81","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1084\/jem.193.2.255","article-title":"Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2","volume":"193","author":"Hirai","year":"2001","journal-title":"J. Exp. Med."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553921000420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553921000420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:30:20Z","timestamp":1761082220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553921000420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":78,"alternative-id":["S1094553921000420"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2021.102030","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2021.102030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102030"}}